Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension

The diagnosis of pulmonary arterial hypertension (PAH) is frequently delayed. We hypothesized that circulating angiogenic modulatory protein levels might correspond with vascular remodeling activity and serve as sensitive biomarkers of PAH. Levels of soluble endoglin (sEng), soluble vascular endothelial growth factor receptor-1 (sVEGFR1), N-terminal brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), and other biomarkers were measured in peripheral blood from 97 PAH patients, 16 first-degree relatives of idiopathic or heritable pulmonary arterial hypertension (HPAH) patients, and 56 controls, and correlated with disease, functional class, hemodynamic parameters, exercise capacity, and transplant-free survival. Endoglin expression was analyzed in lung tissues of six individuals with idiopathic or HPAH and four individuals without PAH. Levels of sEng, sVEGFR1, CRP, and NT-proBNP were elevated in Group I PAH of diverse etiologies, with sEng performing better than NT-proBNP in detecting PAH (receiver operator characteristic-area-under-the curve [ROC-AUC] of 0.82 ± 0.03 vs. 0.71 ± 0.05, P = 0.016). While sEng, sVEGFR1, and NT-proBNP correlated with New York Heart Association (NYHA) class, sEng levels were more sensitive than NT-proBNP in detecting NYHA Class I-II disease (ROC-AUC of 0.88 ± 0.05 vs. 0.67 ± 0.08, P = 0.028). sEng, sVEGFR1, CRP, and NT-proBNP predicted transplant-free survival by univariate Cox regression. After adjusting for NT-proBNP levels, each of the other three markers predicted transplant-free survival. In multivariate analysis, sEng and CRP were independent predictors of survival. Endoglin expression was markedly enhanced in the microvascular endothelium and endovascular lesions of PAH versus control lung tissues. Circulating angiogenic proteins sEng and sVEGFR1 are sensitive markers of prognosis and function in Group I PAH, including mildly symptomatic disease, and may provide unique noninvasive data reflecting underlying remodeling activity.

[1]  Xavier Jaïs,et al.  [Treatment of pulmonary arterial hypertension]. , 2014, Presse medicale.

[2]  M. Gatzoulis,et al.  [Updated clinical classification of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[3]  D. Kass,et al.  Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure , 2012, Circulation.

[4]  B. Dahal,et al.  Integrative Physiology/experimental Medicine Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension Materials and Methods Mct Treatment, Inhibitor Treatment, and Hemodynamic Measurements Assessment of Vascular Remodeling and Proliferation in Situ Cell Culture Proliferation Assays Chemot , 2022 .

[5]  M. Humbert,et al.  Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .

[6]  A. Morton,et al.  Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension , 2012, Pulmonary circulation.

[7]  Daniel Dumitrescu,et al.  Imatinib mesylate for the treatment of pulmonary arterial hypertension , 2012, Expert opinion on investigational drugs.

[8]  S. Hazen,et al.  Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension , 2011, European Respiratory Journal.

[9]  N. Solban,et al.  Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth* , 2011, The Journal of Biological Chemistry.

[10]  C. Bokemeyer,et al.  Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? , 2011, BMC pulmonary medicine.

[11]  K. Ataga,et al.  Association of soluble fms‐like tyrosine kinase‐1 with pulmonary hypertension and haemolysis in sickle cell disease , 2011, British journal of haematology.

[12]  G. Heresi.  Clinical perspective: biomarkers in pulmonary arterial hypertension , 2011, International journal of clinical practice. Supplement.

[13]  J. López-Novoa,et al.  The physiological role of endoglin in the cardiovascular system. , 2010, American journal of physiology. Heart and circulatory physiology.

[14]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[15]  N. Voelkel,et al.  Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension , 2010, Circulation.

[16]  W. Seeger,et al.  Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. , 2010, Chest.

[17]  H. Verspaget,et al.  Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. , 2010, Cancer research.

[18]  Florence T. H. Wu,et al.  A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use , 2009, Journal of cellular and molecular medicine.

[19]  T. Nawrot,et al.  C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[20]  Jeffrey L. Anderson,et al.  ACCF/AHA Expert Conseusus Document , 2009 .

[21]  J. Freyssinet,et al.  Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[22]  David Evans,et al.  Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. , 2008, The American journal of pathology.

[23]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[24]  P. Geborek,et al.  Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease , 2007, Arthritis research & therapy.

[25]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[26]  J. Foster,et al.  NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension , 2007, European Respiratory Journal.

[27]  K. Lewis.  Pulmonary Arterial Hypertension in France: Results from a National Registry , 2007 .

[28]  Y. Çelik,et al.  Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. , 2007, Thrombosis research.

[29]  Lu Tian,et al.  Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease , 2006, Annals of Internal Medicine.

[30]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[31]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[32]  H. Parving,et al.  Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. , 2006, European journal of endocrinology.

[33]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[34]  W. Seeger,et al.  Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[35]  Toshio Ogihara,et al.  Serum interleukin-15 concentration in patients with essential hypertension. , 2005, American journal of hypertension.

[36]  B. Rudensky,et al.  C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease. , 2005, Blood cells, molecules & diseases.

[37]  D. Eidelman,et al.  Downloaded from http://circres.ahajournals.org / by guest on February 23, 2013A Role for Endoglin in Coupling eNOS Activity and Regulating Vascular Tone Revealed in Hereditary , 2022 .

[38]  R. Gaiser,et al.  Circulating Angiogenic Factors and the Risk of Preeclampsia , 2005 .

[39]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[40]  K. Dickstein,et al.  Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[41]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[42]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[43]  Y. Ikari,et al.  Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.

[44]  P. Geusens,et al.  Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic Plaques , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[45]  H. Hashimoto,et al.  Serum levels of interleukin 15 in patients with rheumatic diseases. , 2001, The Journal of rheumatology.

[46]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[47]  P. Eriksson,et al.  Expression of interleukin-15 in mouse and human atherosclerotic lesions. , 2001, The American journal of pathology.

[48]  N. Voelkel,et al.  Primary pulmonary hypertension between inflammation and cancer. , 1998, Chest.

[49]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[50]  H. Kanegane,et al.  Interleukin-15 promotes angiogenesis in vivo. , 1997, Biochemical and biophysical research communications.

[51]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[52]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[53]  J. V. van Mourik,et al.  Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.

[54]  D. Heath.  Pulmonary hypertension in pulmonary parenchymal disease. , 1972, Cardiovascular clinics.